NCT06391008View on ClinicalTrials.gov

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

June 30, 2025

Conditions
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
Interventions
RADIATION

Stereotactic radiotherapy

Targeting primary lung lesions and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy was performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f

DRUG

Evoximab

Evoximab (20mg/kg, Q3W)

DRUG

Pemetrexed

Pemetrexed (500mg/m2, Q3W)

DRUG

Albumin Paclitaxel

Albumin Paclitaxel 260 mg/m2, Q3W

DRUG

Carboplatin

Carboplatin (AUC5, Q3W)

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT06391008 - Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter